
Please try another search
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Jinhao Du | 71 | 2019 | Chairman of the Board & GM |
Guo Yang | 36 | 2019 | Director |
Lijun Wang | 44 | 2023 | Employee Representative Supervisor |
Feng Xu | 60 | 2019 | Deputy GM & Director |
Jun Yan | 43 | 2019 | Independent Director |
Ronggang Xie | 39 | 2019 | Director |
Ju Qi | 73 | 2019 | Director |
Xiaofang Zhang | 50 | 2023 | Chairman of Supervisory Board |
Chao Lu | 43 | 2019 | Independent Director |
Cong Xu | 40 | 2024 | Director |
Jie Hu | 50 | 2019 | Vice Chairman & Deputy GM |
Jiayu Yang | 46 | 2019 | Independent Director |
Shengming Chu | 55 | 2023 | Supervisor |
Shengtao Zhu | 47 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review